Amylin Sues Lilly Over Byetta Sales Plans

Law360, New York (May 16, 2011, 4:56 PM EDT) -- Amylin Pharmaceuticals Inc. said Monday it had sued Eli Lilly & Co. in California, claiming Lilly’s plans to use the same sales force to sell both Amylin’s diabetes treatment and a rival one are anti-competitive and in breach of a marketing deal.

Amylin joined forces with Lilly in 2002 to develop and commercialize exenatide, a treatment for Type 2 diabetes currently marketed as Byetta. But when Lilly also announced a global alliance with Boehringer Ingelheim GmbH to develop and commercialize the rival diabetes treatment linagliptin, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.